| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$24 |
Galileo Mining - Investor Presentation November 2025
|
17 Nov 2025 8:36AM |
$0.205 |
$0.120 |
fallen by
41.46%
|
|
| Elders Limited (ELD) ORDINARY FULLY PAID |
Consumer Staple |
$1,245 |
Elders FY25 Results Announcement
|
17 Nov 2025 8:36AM |
$6.970 |
$5.780 |
fallen by
17.07%
|
|
ELD - Price-sensitive ASX Announcement
Full Release
Key Points
- Underlying EBIT of $143.5 million for FY25.
- Final dividend of 18 cents per share, fully franked.
- Sales revenue increased by 2% to $3.2 billion.
- Improved safety metrics with a reduced injury frequency rate.
- Optimistic outlook for FY26 with anticipated recovery from dry conditions.
- Incorporation of Delta Agribusiness and new retail system in FY26.
- Commitment to strategic investments and sustainable growth.
- Newly implemented divisional model for increased growth and efficiency.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Meteoric Resources Limited (MEI) ORDINARY FULLY PAID |
Materials |
$567 |
Strategic Land Holding Agreement Finalised
|
17 Nov 2025 8:35AM |
$0.180 |
$0.195 |
risen by
8.33%
|
|
| Elders Limited (ELD) ORDINARY FULLY PAID |
Consumer Staple |
$1,245 |
Dividend/Distribution - ELD
|
17 Nov 2025 8:34AM |
$6.970 |
$5.780 |
fallen by
17.07%
|
|
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$79 |
Update - Notification of buy-back - BOL
|
17 Nov 2025 8:33AM |
$1.425 |
$2.140 |
risen by
50.18%
|
|
| Elders Limited (ELD) ORDINARY FULLY PAID |
Consumer Staple |
$1,245 |
Appendix 4E and Annual Report for Year Ended 30/9/2025
|
17 Nov 2025 8:33AM |
$6.970 |
$5.780 |
fallen by
17.07%
|
|
ELD - Price-sensitive ASX Announcement
Full Release
Key Points
- Elders Limited reported an increase in revenue from $3,131 million in 2024 to $3,202 million in 2025.
- Profit before income tax was $71.6 million in 2025, compared to $67.8 million in 2024.
- Total comprehensive income for 2025 was $59.1 million.
- Net operating cash flows increased to $117.9 million from $82.9 million in 2024.
- Investments in property, plant, and equipment amounted to $16 million.
- Elders raised $245.8 million from the issuance of new shares.
- Total assets increased to $2,484 million with net assets at $1,085 million.
- The company made strategic and transformational expenditures that increased corporate overheads.
- Segments like Tasmania and Western Australia showed improved EBIT.
- Equity accounted investments amounted to $51.9 million in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hearts and Minds Investments Limited (HM1) ORDINARY FULLY PAID |
Financials |
$671 |
Weekly NTA Estimate
|
17 Nov 2025 8:30AM |
$3.140 |
$2.930 |
fallen by
6.69%
|
|
| Tivan Limited (TVN) ORDINARY FULLY PAID |
Materials |
$581 |
Tivan and ETFS execute binding agreements for Speewah
|
17 Nov 2025 8:30AM |
$0.215 |
$0.250 |
risen by
16.28%
|
|
TVN - Price-sensitive ASX Announcement
Full Release
Key Points
- Tivan and ETFS Capital signed binding agreements for up to $61.3 million investment in the Speewah Fluorite Project.
- ETFSC is set to invest up to $51.3 million in Fluorite Holding SPV Pty Ltd for 17.5% share of the project.
- The investment is structured in two tranches, with an initial $11.3 million in January 2026 and a final tranche of $40 million.
- ETFSC also agreed to provide a $10 million overrun equity facility for additional project funding.
- Tivan aims to develop Australia's first fluorite mining and processing operation.
- Sumitomo Corporation and Japan Organization for Metals and Energy Security are also strategic partners in the project.
- The project is located in the Kimberley region of north-east Western Australia.
- Tivan will retain a 60% interest in the Speewah Fluorite Project upon completion of all project funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ramsay Health Care Limited (RHC) ORDINARY FULLY PAID |
Health Care |
$10,364 |
Appointment of Group Chief Financial Officer
|
17 Nov 2025 8:30AM |
$30.920 |
$44.900 |
risen by
45.21%
|
|
| Meteoric Resources Limited (MEI) ORDINARY FULLY PAID |
Materials |
$567 |
Proposed issue of securities - MEI
|
17 Nov 2025 8:29AM |
$0.180 |
$0.195 |
risen by
8.33%
|
|
| Fortuna Metals Ltd (FUN) ORDINARY FULLY PAID |
Materials |
$42 |
Exceptional Rutile Results up to 2.32% in Soils
|
17 Nov 2025 8:29AM |
$0.130 |
$0.100 |
fallen by
23.08%
|
|
FUN - Price-sensitive ASX Announcement
Full Release
Key Points
- Exceptional rutile results up to 2.32% in soil samples.
- First-pass reconnaissance identifies potential drilling sites.
- 50% of sampled locations returned over 1.0% rutile.
- Further analysis of 166 samples expected by late November 2025.
- Drilling planned for dry season 2026 to infill high-grade areas.
- Projects cover 658km², located near Lilongwe and infrastructure.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iondrive Limited (ION) ORDINARY FULLY PAID |
Materials |
$69 |
Positive Techno-Economic Evaluation for REE Recycling
|
17 Nov 2025 8:28AM |
$0.045 |
$0.053 |
risen by
17.78%
|
|
ION - Price-sensitive ASX Announcement
Full Release
Key Points
- Iondrive Limited completed a Phase 1 techno-economic evaluation for its IONSolvTM technology platform for a 2ktpa modular REE recycling plant.
- The study confirms that the IONSolvTM process can derive value from waste magnets, supporting a scalable modular rollout across U.S. sites.
- Economic modeling indicates a post-tax NPV of US $7M, a post-tax IRR of 46%, and a payback period of 2.6 years.
- The Phase 1 study found that the average annual production rate is approximately 115 tonnes of mixed rare-earth oxides over a ten-year operating life.
- Phase 2 laboratory validation is underway to confirm process assumptions and refine economic modeling before plant engineering.
- The IONSolvTM technology is a Deep Eutectic Solvent (DES) process for REE recovery and is noted for complementing other recycling initiatives for batteries and solar panels.
- The study suggests that Iondrive can help reduce North America's reliance on imported REEs and strengthen critical mineral supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$4,998 |
Notification regarding unquoted securities - ANN
|
17 Nov 2025 8:28AM |
$36.560 |
$35.620 |
fallen by
2.57%
|
|
| Calix Limited (CXL) ORDINARY FULLY PAID |
Materials |
$68 |
Joint Development Agreement (JDA) with Rio Tinto for Zesty
|
17 Nov 2025 8:28AM |
$0.465 |
$0.315 |
fallen by
32.26%
|
|
CXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Calix Limited has executed a Joint Development Agreement (JDA) with Rio Tinto for the Zesty Green Iron Demonstration Plant.
- Rio Tinto will contribute over $35 million in cash and in-kind support to the project.
- The project aims to demonstrate and commercialize Calix's Zero Emissions Steel Technology (Zesty).
- The Zesty Demonstration Plant will be located in Kwinana, Western Australia.
- The project is supported by a grant of up to $44.9 million from the Australian Renewable Energy Agency (ARENA).
- Rio Tinto's contribution includes technical support, engineering services, and the provision of Pilbara Iron Ores.
- The JDA allows Rio Tinto to potentially take up shares in a Zesty subsidiary business.
- The Zesty technology aims to produce green iron and steel using electric heating and hydrogen reduction.
- The project is expected to reach a Final Investment Decision (FID) by 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$52 |
RAD Announces 50% Enrollment in Phase 2b Trial of RAD101
|
17 Nov 2025 8:28AM |
$0.022 |
$0.012 |
fallen by
45.45%
|
|
RAD - Price-sensitive ASX Announcement
Full Release
Key Points
- Radiopharm Theranostics reached 50% enrollment in Phase 2b trial of RAD101.
- RAD101 targets fatty acid synthase overexpressed in tumors.
- Early data shows promising tumor uptake in brain metastases.
- Phase 2b trial results expected in first half of 2026.
- RAD101 has FDA Fast Track Designation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$20,774 |
Update - Notification of buy-back - PME
|
17 Nov 2025 8:28AM |
$248.830 |
$198.850 |
fallen by
20.09%
|
|
| DataWorks Group Limited (DWG) ORDINARY FULLY PAID |
Information Technology |
$15 |
Strong BetStop Outcomes and Operational Excellence Reported
|
17 Nov 2025 8:28AM |
$0.056 |
$0.145 |
risen by
158.93%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$79,729 |
Update - Notification of buy-back - CSL
|
17 Nov 2025 8:28AM |
$181.810 |
$166.480 |
fallen by
8.43%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,214 |
Update - Notification of buy-back - ZIP
|
17 Nov 2025 8:28AM |
$3.140 |
$2.580 |
fallen by
17.83%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$23 |
First dose in HERACLES clinical trial Part Two
|
17 Nov 2025 8:27AM |
$0.090 |
$0.076 |
fallen by
15.56%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- First dosing in HERACLES Part Two starts.
- SOF-SKNâ„¢ tested for autoimmune diseases.
- Trial conducted in Australia for tax benefits.
- Phase I trial evaluates safety and tolerability.
- Two cohorts receive daily doses for two weeks.
- Focus on real-world application of treatments.
- Noxopharm collaborates with Doherty Clinical Trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HighCom Limited (HCL) ORDINARY FULLY PAID |
Industrials |
$13 |
HighCom Armor Business Update
|
17 Nov 2025 8:27AM |
$0.285 |
$0.092 |
fallen by
67.72%
|
|
| FSA Group Limited (FSA) ORDINARY FULLY PAID |
Financials |
$160 |
Update - Notification of buy-back - FSA
|
17 Nov 2025 8:27AM |
$1.235 |
$1.300 |
risen by
5.26%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$26,006 |
Update - Notification of buy-back - BXB
|
17 Nov 2025 8:27AM |
$23.660 |
$19.470 |
fallen by
17.71%
|
|
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$3,046 |
Net Tangible Asset Backing
|
17 Nov 2025 8:27AM |
$3.580 |
$4.800 |
risen by
34.08%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$550 |
Weekly NTA 14.11.2025
|
17 Nov 2025 8:26AM |
$3.250 |
$2.470 |
fallen by
24%
|
|